SCHEMBL4335405

SCHEMBL4335405

Cc1cccc(C(C)C(=O)Nc2onc(-c3ccc(F)cc3F)c2-c2ccncc2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 8/20 0.48
MLYCD O95822 1/20 0.44
PSEN1 P49768 2/20 0.43
PSEN2 P49810 2/20 0.43
APH1B Q8WW43 2/20 0.43
NCSTN Q92542 2/20 0.43
APH1A Q96BI3 2/20 0.43
PSENEN Q9NZ42 2/20 0.43
LMNA P02545 4/20 0.40
SMN1; SMN2 Q16637 4/20 0.40
MAPT P10636 3/20 0.40
HTT P42858 2/20 0.40
AKR1C3 P42330 2/20 0.40
AKR1C2 P52895 2/20 0.40
NPSR1 Q6W5P4 2/20 0.40
FAAH O00519 1/20 0.39
POLB P06746 1/20 0.39
KMT2A Q03164 2/20 0.38
MEN1 O00255 1/20 0.38
HSD17B10 Q99714 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4337180 0.91 MAPK14 (0.52) MAPK14MLYCDLMNASMN1; SMN2MAPT
SCHEMBL4335362 0.90 MAPK14 (0.51) MAPK14MLYCDPSEN1PSEN2APH1B
SCHEMBL4337080 0.89 MLYCD (0.45) MAPK14MLYCDPSEN1PSEN2APH1B
SCHEMBL4335452 0.87 PSEN1 (0.46) MAPK14MLYCDPSEN1PSEN2APH1B
SCHEMBL4332793 0.85 MAPK14 (0.51) MAPK14MLYCDPSEN1PSEN2APH1B
SCHEMBL4338188 0.85 MAPK14 (0.51) MAPK14MLYCDPSEN1PSEN2APH1B
SCHEMBL4348725 0.85 MAPK14 (0.50) MAPK14MLYCDLMNASMN1; SMN2MAPT
SCHEMBL4331788 0.83 MLYCD (0.43) MAPK14MLYCDPSEN1PSEN2APH1B
SCHEMBL4337504 0.83 MAPK14 (0.58) MAPK14MLYCD
SCHEMBL4342451 0.82 MAPK14 (0.47) MAPK14MLYCDLMNASMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2036905-B1 PYRIDYLISOXAZOLE DERIVATIVE ASKA PHARM CO LTD (JP) 2012-12-12 EP disclosed
US-8207203-B2 Pyridylisoxazole derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2012-06-26 US disclosed
US-20090306145-A1 Pyridylisoxazole Derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2009-12-10 US disclosed
EP-2036905-A1 PYRIDYLISOXAZOLE DERIVATIVE ASKA Pharmaceutical Co., Ltd. (JP) 2009-03-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306145-A1 Pyridylisoxazole Derivatives CNKSR1, MAPK1, MAPK3 MAPK14 43/4885MLYCD 4475/4885PSEN1 4493/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.